A Dark Vector Cognition product

Item 1. CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

74K characters. Original on sec.gov ·

Item 1. CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

The 34 tables in Item 1. CONDENSED CONSOLIDATED FINANCIAL STATEMENTS as one CSV, figures in aligned columns. For subscribers: paste your API key. One API call. Plans from $19 a month, see pricing.

CONDENSED CONSOLIDATED STATEMENTS OF EARNINGS

AND COMPREHENSIVE INCOME

Bio-Techne Corporation and Subsidiaries

(in thousands, except per share data)

(unaudited)

​

​​​​​​​
​Quarter Ended
​​September 30,
​​2022​2021
​​​​​​​
Net sales​$269,655​$257,719
Cost of sales​90,060​86,722
Gross margin​179,595​170,997
​​​​​​​
Operating expenses:​​
Selling, general and administrative​99,375​86,175
Research and development​23,903​21,600
Total operating expenses​123,278​107,775
Operating income​56,317​63,222
​​​​​​​
Other income (expense)​47,399​​4,161
Earnings before income taxes​103,716​67,383
Income taxes (benefit)​13,982​(1,598)
Net earnings, including noncontrolling interest​89,734​68,981
Net earnings (loss) attributable to noncontrolling interest​179​(634)
Net earnings attributable to Bio-Techne​$89,555​$69,615
Other comprehensive income (loss):​​
Foreign currency translation adjustments​(21,457)​(8,646)
Foreign currency translation reclassified to earnings with Eminence deconsolidation​​119​​—
Unrealized gains (losses) on derivative instruments - cash flow hedges, net of tax amounts disclosed in Note 8​4,695​1,682
Other comprehensive income (loss)​(16,643)​(6,964)
Other comprehensive income (loss) attributable to noncontrolling interest​(33)​(39)
Other comprehensive income (loss) attributable to Bio-Techne​(16,610)​(6,925)
Comprehensive income attributable to Bio-Techne​$72,945​$62,690
​​​​​​​
Earnings per share attributable to Bio-Techne:​​​​​
Basic​$2.28​$1.78
Diluted​$2.21​$1.69
​​​​​​​
Weighted average common shares outstanding:​​​
Basic​39,232​39,094
Diluted​40,543​41,158

​

See Notes to Condensed Consolidated Financial Statements.

​

CONDENSED CONSOLIDATED BALANCE SHEETS

Bio-Techne Corporation and Subsidiaries

(in thousands, except share and per share data)

​

​​​​​​​
​September 30,​​​
​​2022​June 30,
​​(unaudited)​2022
ASSETS​​
Current assets:​​
Cash and cash equivalents​$165,257​$172,567
Short-term available-for-sale investments​37,818​74,462
Accounts receivable, less allowance for doubtful accounts of $2,496 and $2,568, respectively​174,174​194,548
Inventories​150,009​141,123
Other current assets​24,773​22,856
Total current assets​552,031​605,556
​​​​​​​
Property and equipment, net​224,098​223,242
Right of use asset​69,745​65,556
Goodwill​865,418​822,101
Intangible assets, net​585,534​531,522
Other assets​53,895​46,828
Total assets​$2,350,721​$2,294,805
LIABILITIES AND SHAREHOLDERS’ EQUITY​​
Current liabilities:​​
Trade accounts payable​$30,475​$33,865
Salaries, wages and related accruals​32,557​61,953
Accrued expenses​13,790​17,886
Contract liabilities​22,059​23,406
Income taxes payable​17,270​13,237
Operating lease liabilities - current​12,115​11,928
Contingent consideration payable​7,400​—
Current portion of long-term debt obligations​—​12,500
Other current liabilities​1,963​1,243
Total current liabilities​137,629​176,018
​​​​​​​
Deferred income taxes​112,920​98,994
Long-term debt obligations​264,661​243,410
Long-term contingent consideration payable​8,100​5,000
Operating lease liabilities​64,756​58,133
Other long-term liabilities​11,501​12,239
​​​
Bio-Techne’s Shareholders’ equity:​​​​​​
Undesignated capital stock, no par; authorized 5,000,000 shares; none issued or outstanding​—​—
Common stock, par value $.01 per share; authorized 100,000,000; issued and outstanding 39,232,094 and 39,160,000, respectively​392​392
Additional paid-in capital​680,057​653,657
Retained earnings​1,162,515​1,122,921
Accumulated other comprehensive loss​(91,810)​(75,200)
Total Bio-Techne’s shareholders’ equity​1,751,154​1,701,770
Noncontrolling interest​—​(759)
Total shareholders’ equity​1,751,154​1,701,011
Total liabilities and shareholders’ equity​$2,350,721​$2,294,805

​

See Notes to Condensed Consolidated Financial Statements.

​

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

Bio-Techne Corporation and Subsidiaries

(in thousands)

(unaudited)

​

​​​​​​​
​Quarter Ended
​​September 30,
​​2022​2021
CASH FLOWS FROM OPERATING ACTIVITIES:​​
Net earnings, including noncontrolling interest​$89,734​$68,981
Adjustments to reconcile net earnings to net cash provided by operating activities:​​
Depreciation and amortization​26,641​24,734
Costs recognized on sale of acquired inventory​300​1,512
Deferred income taxes​(4,767)​5,407
Stock-based compensation expense​14,461​11,737
Fair value adjustment to contingent consideration payable​(100)​(2,800)
Contingent consideration payments - operating​—​(3,300)
(Gain) Loss on investment, net​(37,176)​(5,277)
Fair value adjustment on available for sale investments​(911)​—
Asset impairment restructuring​​—​​546
Gain on sale of Eminence​​(11,682)​​—
Leases, net​2,545​(79)
Other operating activity​(32)​497
Change in operating assets and operating liabilities, net of acquisition:​​
Trade accounts and other receivables, net​17,335​(3,637)
Inventories​(10,685)​(2,981)
Prepaid expenses​(2,760)​(5,852)
Trade accounts payable, accrued expenses, contract liabilities, and other​(1,401)​(2,303)
Salaries, wages and related accruals​(28,360)​(18,933)
Income taxes payable​2,939​(19,818)
Net cash provided by (used in) operating activities​56,081​48,434
​​​​​​​
CASH FLOWS FROM INVESTING ACTIVITIES:​​
Proceeds from maturities of available-for-sale investments​14,509​12,450
Purchases of available-for-sale investments​(14,500)​(13,500)
Proceeds from sale of CCXI investment​​73,219​​—
Additions to property and equipment​(9,556)​(6,070)
Acquisitions, net of cash acquired​(101,184)​—
Proceeds from sale of Eminence​17,824​—
Net cash provided by (used in) investing activities​(19,688)​(7,120)
​​​​​​​
CASH FLOWS FROM FINANCING ACTIVITIES:​​
Cash dividends​(12,545)​(12,493)
Proceeds from stock option exercises​11,950​37,880
Re-purchases of common stock​(19,562)​—
Borrowings under line-of-credit agreement​449,661​10,000
Repayments of long-term debt​(441,000)​(51,125)
Contingent consideration payments - financing​—​(700)
Taxes paid on RSUs and net share settlements​​(17,853)​​(23,246)
Other financing activity​(2,457)​—
Net cash provided by (used in) financing activities​(31,806)​(39,684)
​​​​​​​
Effect of exchange rate changes on cash and cash equivalents​(11,897)​(4,400)
Net change in cash and cash equivalents​(7,310)​(2,770)
Cash and cash equivalents at beginning of period​172,567​199,091
Cash and cash equivalents at end of period​$165,257​$196,321
​​​​​​​
Supplemental disclosure of cash flow information:​​​​​​
Cash paid for income taxes​$14,892​$12,070
Cash paid for interest​$3,409​$3,107

​

See Notes to Condensed Consolidated Financial Statements.

​

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

Bio-Techne Corporation and Subsidiaries

(unaudited)

Note 1. Basis of Presentation and Summary of Significant Accounting Policies:

The interim consolidated financial statements of Bio-Techne Corporation and subsidiaries, (the Company) presented here have been prepared by the Company and are unaudited. They have been prepared in accordance with accounting principles generally accepted in the United States of America and with instructions to Form 10-Q and Article 10 of Regulation S-X. They reflect all adjustments which are, in the opinion of management, necessary for a fair presentation of the results for the interim periods presented. All such adjustments are of a normal recurring nature.

Certain information and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America have been condensed or omitted. These interim unaudited condensed consolidated financial statements should be read in conjunction with the Company's Consolidated Financial Statements and Notes thereto for the fiscal year ended June 30, 2022, included in the Company's Annual Report on Form 10-K for fiscal 2022. A summary of significant accounting policies followed by the Company is detailed in the Company's Annual Report on Form 10-K for fiscal 2022. The Company follows these policies in preparation of the interim unaudited condensed consolidated financial statements.

During the quarter ended September 30, 2022, the Company operated under two operating segments, Protein Sciences and Diagnostics and Genomics. The operating segments the Company operated under were consistent with the Company's operating segments disclosed in the Company's Annual Report on Form 10-K for fiscal 2022.

Partially-owned consolidated subsidiary: On September 1, 2022, the Company completed the sale of its equity shares of Changzhou Eminence Biotechnology Co., Ltd. (Eminence) for approximately $17.8 million to a third party. Eminence was considered a variable-interest entity that was fully consolidated in our financial statements. Prior to the sale, Eminence had revenue of $2.0 million for the first fiscal quarter of 2023 within our Protein Sciences segment. Fiscal 2022 revenues were $4.6 million. As a result of the sale of the business, the Company recorded a gain of $11.7 million within the Other income (expense) line in the Condensed Consolidated Statement of Earnings. Prior to the sale of Eminence, a triggering event was identified in the second quarter of fiscal 2022 and impairment testing was performed as Eminence was forecasted to not have sufficient cash to execute on their growth plan combined with their inability to secure additional financing. Our impairment testing resulted in a full impairment of the Eminence goodwill and intangibles assets for charges of $8.3 million and $8.6 million, respectively, for the year ended June 30, 2022. The Company also recognized inventory and fixed asset impairment charges of $0.9 million and $0.9 million, respectively. These impairment charges were recorded within the General and Administrative line in the Consolidated Statement of Earnings for fiscal 2022. In the fourth quarter of fiscal 2022, Eminence was able to secure cash deposits on future orders to provide funding for their operations. This delay in liquidation allowed time for securing of additional investor financing which coincided with the sale of the Company's investment.

Investments: In December 2021, the Company paid $25 million to enter into a two-part forward contract which requires the Company to make an initial ownership investment followed by purchase of full equity interest in Wilson Wolf Corporation (Wilson Wolf) if certain annual revenue or EBITDA thresholds are met. Wilson Wolf is a leading manufacturer of cell culture devices, including the G-Rex product line.

The first part of the forward contract is triggered upon Wilson Wolf achieving approximately $92 million in annual revenue or $55 million in annual earnings before interest, taxes, depreciation, and amortization (EBITDA) at any point prior to December 31, 2027. Once triggered, the Company is required to make a payment of $231 million in exchange for a 19.9% ownership stake. If Wilson Wolf doesn’t achieve the revenue and EBITDA targets by December 31, 2027, the agreement will expire.

Once the first part of the forward contract is triggered, the second part of the forward contract will automatically trigger, and requires the Company to acquire the remaining equity interest in Wilson Wolf on December 31, 2027 based on a revenue multiple. The second part of the contract would be accelerated in advance of December 31, 2027, if Wilson Wolf meets its second milestone of approximately $226 million in annual revenue or $136 million in annual EBITDA. If the second milestone is achieved, the forward contract requires the Company to pay approximately $1 billion plus potential consideration for revenue in excess of the revenue milestone. The approximate multiple for total expected payments of the second forward contract is 4.4 times the annual revenue of Wilson Wolf. The Company has elected to apply the measurement alternative as detailed under ASC 321-10-35-2 for the Wilson Wolf investment. The Company recorded the $25 million payment as a cost basis investment within Other long-term assets on the Consolidated Balance Sheet.

Restructuring actions: Restructuring actions generally include significant actions involving employee-related severance charges, contract termination costs, and impairments and disposals of assets associated with such actions. Employee-related severance charges are based upon distributed employment policies and substantive severance plans. These charges are reflected in the quarter when the actions are probable and the amounts are estimable, which typically is when management approves the associated actions. Asset impairment and disposal charges include right of use assets, leasehold improvements, and other asset write-downs associated with combining operations and disposal of assets.

Fiscal Year 2023 Restructuring Actions:

In August 2022, the Company informed employees of our decision to close our QT Holdings Corporation (Quad) facility as part of a realignment of activities within our Reagent Solutions division. The closure of the site is expected to be substantially completed in the third quarter of fiscal 2023. As a result of the restructuring activities, an estimated pre-tax charge of $2.2 million was recorded within our Protein Sciences segment. The related first quarter of fiscal 2023 restructuring charges were recorded in the income statement as follows (in thousands):

​

​​​​​​​​​​
​​​​​​​​​​
​​Employee​Asset​​
​severancerelated and otherTotal
Selling, general and administrative​$1,328​$842​$2,170

​

Restructuring actions, including cash and non-cash impacts, are as follows (in thousands):

​

​​​​​​​​​​
​​Employee​Asset​​
​severancerelated and otherTotal
Expense incurred in the first quarter of 2023​$1,328​$842​$2,170
Cash payments​​(420)​​(431)​​(851)
Adjustments​​—​​(72)​​(72)
Accrued restructuring actions balances as of September 30, 2022​$908​​339​​1,247

​

Fiscal Year 2022 Restructuring Actions:

​

In September 2021, the Company informed employees of our decision to close our Exosome Diagnostics Germany facility, discontinuing lab and research occurring at the site, as part of a realignment of activities within our Exosome Diagnostics business. The restructuring activities were complete as of June 30, 2022. As a result of the restructuring activities, a pre-tax charge of $1.4 million was recorded within our Diagnostics and Genomics segment during the year ended June 30, 2022. Total restructuring charges for the closure of the Exosome Diagnostics Germany facility for the year ended June 30, 2022 were recorded within operating income on the income statement as follows (in thousands):

​

:​​​​​​​​​
​​Employee​Asset​​
​severanceImpairment and otherTotal
Selling, general and administrative​$649​$750​$1,399

​

​​​​​​​​​​
​​Employee​Asset​​
​severanceImpairment and otherTotal
Expense incurred in the first quarter of 2022​$639​$546​$1,185
Incremental expense incurred during fiscal 2022​​—​​242​​242
Cash payments​​(589)​​(554)​​(1,143)
Adjustments(1)​​(50)​​(234)​​(284)
Accrued restructuring actions balances as of June 30, 2022​$—​​—​​—

(1)Adjustments include refinements to our estimated close down costs as well as the impacts from foreign currency exchange.

​

Recently Adopted Accounting Pronouncements

There were no accounting pronouncements adopted in the quarter ended September 30, 2022. Refer to the Form 10-K for accounting pronouncements adopted prior to June 30, 2022.

​

Note 2. Revenue Recognition:

Consumables revenues consist of specialized proteins, immunoassays, antibodies, reagents, blood chemistry and blood gas quality controls, and hematology instrument controls that are typically single-use products recognized at a point in time following the transfer of control of such products to the customer, which generally occurs upon shipment. Instruments revenues typically consist of longer-lived assets that, for the substantial majority of sales, are recognized at a point in time in a manner similar to consumables. Service revenues consist of extended warranty contracts, post contract support, and custom development projects that are recognized over time as either the customers receive and consume the benefits of such services simultaneously or the underlying asset being developed has no alternative use for the Company at contract inception and the Company has an enforceable right to payment for the portion of the performance completed. Service revenues also include laboratory services recognized at point in time.

Prior to fiscal year 2021, the Company had not recognized revenue upon completion of the performance obligation for laboratory services, but rather upon cash receipt, which was subsequent to the performance obligation being satisfied. The Company accounted for these services based on cash receipts as we did not have significant historical experience collecting payments from Medicare or other insurance providers and considered the variable consideration for such services to be constrained as it would not be probable that a significant amount of revenue would not need to be reversed in future periods for the services provided. Given Medicare coverage for our laboratory services became effective on December 1, 2019, the Company considered it to have sufficient data to estimate variable consideration as of July 1, 2020 for laboratory services that are reimbursed by Medicare. The amount of cash received in fiscal 2021 for laboratory services reimbursed by Medicare that were performed prior to July 1, 2020 was approximately $0.5 million.

Prior to fiscal year 2023, the Company recorded revenue based on cash receipts for laboratory services not reimbursed by Medicare, as the variable consideration was constrained since we did not have significant historical experience collecting payments not reimbursed by Medicare or other insurance providers and it would not be probable that a significant amount of revenue would not need to be reversed in future periods for the services provided. During the first half of fiscal 2022, we began to see an increase in claim volume due to strategic initiatives, including broader messaging around the importance of cancer screenings during the COVID-19 pandemic, and the acute phase of the COVID-19 pandemic subsiding. Given these factors, the Company considered it to have sufficient data to estimate variable consideration as of July 1, 2022 for laboratory services that are not reimbursed by Medicare. The amount of cash received in fiscal 2023 for non-Medicare laboratory services that were performed prior to July 1, 2022 was approximately $0.7 million.

We recognize royalty revenues in the period the sales occur using third party evidence. The Company elected the "right to invoice" practical expedient based on the Company's right to invoice a customer at an amount that approximates the value to the customer and the performance completed to date.

The Company elected the exemption to not disclose the unfulfilled performance obligations for contracts with an original length of one year or less and the exemption to exclude future performance obligations that are accounted under the sales-based or usage-based royalty guidance. The Company’s unfulfilled performance obligations for contracts with an original length greater than one year were not material as of September 30, 2022.

Contracts with customers that contain instruments may include multiple performance obligations. For these contracts, the Company allocates the contract’s transaction price to each performance obligation on a relative standalone selling price basis. Allocation of the transaction price is determined at the contracts’ inception.

Payment terms for shipments to end-users are generally net 30 days. Payment terms for distributor shipments may range from 30 to 90 days. Service arrangements commonly call for payments in advance of performing the work (e.g. extended warranty and service contracts), upon completion of the service (e.g. custom development manufacturing) or a mix of both.

Contract assets include revenues recognized in advance of billings. Contract assets are included within other current assets in the accompanying balance sheet as the amount of time expected to lapse until the company's right to consideration becomes unconditional is less than one year. We elected the practical expedient allowing us to expense contract costs that would otherwise be capitalized and amortized over a period of less than one year. Contract assets as of September 30, 2022 are not material.

Contract liabilities include billings in excess of revenues recognized, such as those resulting from customer advances and deposits and unearned revenue on warranty contracts. Contract liabilities as of September 30, 2022 and June 30, 2022 were approximately $24.0 million and $25.5 million, respectively. Contract liabilities as of June 30, 2022 subsequently recognized as revenue during the quarter ended September 30, 2022 were approximately $10.6 million. Contract liabilities in excess of one year are included in Other long-term liabilities on the consolidated balance sheet.

Any claims for credit or return of goods must be made within 10 days of receipt. Revenues are reduced to reflect estimated credits and returns. Although the amounts recorded for these revenue deductions are dependent on estimates and assumptions, historically our adjustments to actual results have not been material.

Taxes collected from customers relating to product sales and remitted to governmental authorities are excluded from revenue. Amounts billed to customers for shipping and handling are included in revenue, while the related shipping and handling costs are reflected in cost of products. We elected the practical expedient that allows us to account for shipping and handling activities that occur after the customer has obtained control of a good as a fulfillment cost, and we accrue costs of shipping and handling when the related revenue is recognized.

The following tables present our disaggregated revenue for the periods presented.

Revenue by type is as follows:

​

​​​​​​​
​Quarter Ended
​​September 30,
​20222021
Consumables​$216,430​$205,691
Instruments​26,458​29,869
Services​21,445​16,257
Total product and services revenue, net​$264,333​$251,817
Royalty revenues​5,322​5,902
Total revenues, net​$269,655​$257,719

​

Revenue by geography is as follows:

​

​​​​​​​
​Quarter Ended
​​September 30,
​20222021
​​​
United States​$155,431​$140,702
EMEA, excluding United Kingdom​46,021​51,543
United Kingdom​11,702​12,478
APAC, excluding Greater China​17,465​17,501
Greater China​31,521​28,433
Rest of World​7,515​7,062
Net Sales​$269,655​$257,719

​

​

​

​

Note 3. Selected Balance Sheet Data:

Inventories:

Inventories consist of (in thousands):

​

​​​​​​​
​September 30,​June 30,
​20222022
​​​​​​​
Raw materials​$76,724​$79,291
Finished goods(1)​78,177​66,943
Inventories, net​$154,901​$146,234

​

(1) Finished goods inventory of $4,892 and $5,111 included within other long-term assets in the respective September 30, 2022 and June 30, 2022, consolidated balance sheet. The inventory is included in long-term assets as it is forecasted to be sold after the 12 months subsequent to the consolidated balance sheet date.

Property and Equipment:

Property and equipment consist of (in thousands):

​

​​​​​​​
​September 30,​June 30,
​20222022
Land​$8,509​$8,572
Buildings and improvements​230,295​229,551
Machinery and equipment​​176,746​​174,813
Construction in progress​24,490​21,729
Property and equipment, cost​440,040​434,665
Accumulated depreciation and amortization​(215,942)​(211,423)
Property and equipment, net​$224,098​$223,242

​

Intangible Assets:

Intangible assets consist of (in thousands):

​

​​​​​​​​
​​September 30,​June 30,​
​​2022​2022​
​​​​​​​​
Developed technology​$613,655​$542,038​
Trade names​146,035​146,457​
Customer relationships​222,131​225,882​
Patents​3,418​3,313​
Other intangibles​6,391​6,306​
Definite-lived intangible assets​991,630​923,996​
Accumulated amortization​(428,796)​(415,174)​
Definite-lived intangibles assets, net​562,834​508,822​
In process research and development​22,700​22,700​
Total intangible assets, net​$585,534​$531,522​

​

​

Changes to the carrying amount of net intangible assets for the period ended September 30, 2022 consist of (in thousands):

​

​​​​
​​​​
Beginning balance​$531,522
Acquisitions​75,600
Other additions​63
Amortization expense​(19,504)
Currency translation​​(2,147)
Ending balance​$585,534

​

The estimated future amortization expense for intangible assets as of September 30, 2022 is as follows (in thousands):

​

​​​​
Remainder 2023$57,712
2024​74,475
2025​71,089
2026​67,285
2027​57,177
Thereafter​235,096
Total​$562,834

​

Goodwill:

Changes to the carrying amount of goodwill for the period ended September 30, 2022 consist of (in thousands):

​

​​​​​​​​​​
​​Diagnostics and​
​​Protein Sciences​Genomics​Total
June 30, 2022​$376,493​$445,608​$822,101
Acquisitions​51,051​​—​​51,051
Currency translation​(7,582)​​(152)​​(7,734)
June 30, 2023​$419,962​$445,456​$865,418

​

We evaluate the carrying value of goodwill in the fourth quarter of each fiscal year and between annual evaluations if events occur or circumstances change that would indicate a possible impairment. The Company performed a quantitative goodwill impairment assessment for all of its reporting units during the fourth quarter of fiscal 2022. No indicators of impairment were identified as part of our assessment.

​

Note 4. Acquisitions:

We periodically complete business combinations that align with our business strategy. Acquisitions are accounted for using the acquisition method of accounting, which requires, among other things, that assets acquired and liabilities assumed be recognized at fair value as of the acquisition date and that the results of operations of each acquired business be included in our consolidated statements of comprehensive income from their respective dates of acquisitions. Acquisition costs are recorded in selling, general and administrative expenses as incurred.

Fiscal year 2023 Acquisitions

Namocell, Inc.

On July 1, 2022, the Company acquired all of the ownership interests of Namocell, Inc. for $101.2 million, net of cash acquired, plus contingent consideration of up to $25 million upon the achievement of certain future revenue thresholds. The Namocell acquisition adds easy-to-use single cell sorting and dispensing platforms that are gentle to cells and preserve cell viability and integrity. The transaction was accounted for in accordance with ASC 805, Business Combinations. The goodwill recorded as a result of the acquisition represents the strategic benefits of growing the Company’s product portfolio and the expected revenue growth from increased market penetration. The goodwill is not deductible for income tax purposes. The business became part of the Protein Sciences operating segment in the first quarter of fiscal year 2023.

The allocation of purchase consideration related to Namocell, Inc is considered preliminary with provisional amounts primarily related to goodwill, intangible assets, working capital, certain tax-related, and contingent liability amounts. The Company expects to finalize the allocation of purchase price within the one-year measurement-period following the acquisition. Net sales and operating loss of this business included in Bio-Techne's consolidated results of operations as of September 30, 2022 were approximately $2.4 million and $0.7 million, respectively. The preliminary estimated fair values of the assets acquired and liabilities assumed as of the acquisition date and as of September 30, 2022 are as follows (in thousands):

​

​​​​
​​​
​Preliminary allocation at acquisition date and at September 30, 2022​
Current assets, net of cash$3,248​
Equipment and other long-term assets405​
Intangible assets:​​​
Developed technologies73,900​
Tradenames700​
Customer relationships900​
Non-competition agreement100​
Goodwill51,051​
Total assets acquired130,304​
​​​​
Liabilities546​
Deferred income taxes, net17,974​
Net assets acquired$111,784​
​​​​
Cash paid, net of cash acquired101,184​
Contingent consideration payable10,600​
Net assets acquired$111,784​

​

Tangible assets and liabilities acquired were recorded at fair value on the date of close based on management's preliminary assessment. The purchase price allocated to developed technology was based on management’s preliminary forecasted cash inflows and outflows and using a relief from royalty method to calculate the fair value of assets purchased. The purchase price allocated to customer relationships and trade names was based on management's preliminary forecasted cash inflows and outflows and using a multiperiod excess earnings method. The amount recorded for developed technology is being amortized with the expense reflected in cost of goods sold in the Condensed Consolidated Statement of Earnings and Comprehensive Income. The amortization period for developed technology is estimated to be 13 years. Amortization expense related to customer relationships is reflected in selling, general and administrative expenses in the Condensed Consolidated Statement of Earnings and Comprehensive Income. The amortization period for customer relationships is estimated to be 4 years. The amount recorded for trade names and the non-competition agreement is being amortized with the expense reflected in selling, general and administrative expenses in the Condensed Consolidated Statement of Earnings and Comprehensive Income. The amortization period for both trade names and the non-competition agreement is estimated to be 3 years. The net deferred income tax liability represents the net amount of the estimated future impact of adjustments for costs to be recognized as intangible asset amortization, which is not deductible for income tax purposes, offset by the deferred tax asset for the preliminary calculation of acquired net operating losses.

​

Note 5**. Fair Value Measurements:**

The Company’s financial instruments include cash and cash equivalents, available for sale investments, derivative instruments, accounts receivable, accounts payable, contingent consideration obligations, and long-term debt.

Fair value is defined as the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants as of the measurement date. This standard also establishes a hierarchy for inputs used in measuring fair value. This standard maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available. Observable inputs are inputs market participants would use in valuing the asset or liability based on

market data obtained from independent sources. Unobservable inputs are inputs that reflect our assumptions about the factors market participants would use in valuing the asset or liability based upon the best information available in the circumstances.

The categorization of financial assets and liabilities within the valuation hierarchy is based upon the lowest level of input that is significant to the fair value measurement. The hierarchy is broken down into three levels. Level 1 inputs are quoted prices in active markets for identical assets or liabilities. Level 2 inputs include quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active, and inputs (other than quoted prices) that are observable for the asset or liability, either directly or indirectly. Level 3 inputs are unobservable for the asset or liability and their fair values are determined using pricing models, discounted cash flow methodologies or similar techniques and at least one significant model assumption or input is unobservable. Level 3 may also include certain investment securities for which there is limited market activity or a decrease in the observability of market pricing for the investments, such that the determination of fair value requires significant judgment or estimation.

The following tables provide information by level for financial assets and liabilities that are measured at fair value on a recurring basis (in thousands):

​

​​​​​​​​​​​​​
​Total​​​​​​​​
​​carrying​​​​​​​​​
​​value as of​Fair Value Measurements Using
​​September 30,​Inputs Considered as
​​2022​Level 1​Level 2​Level 3
​​​​​​​​​​​​
Assets​​​​
Exchange traded securities(1)​$23,318​$23,318​$—​$—
Certificates of deposit(2)​14,500​14,500​—​—
Derivative instruments - cash flow hedges​16,685​—​16,685​—
Total assets​$54,503​$37,818​$16,685​$—
​​​​​​​​​​​​​
Liabilities​​​​
Contingent consideration​$15,500​$—​$—​$15,500
Total liabilities​$15,500​$—​$—​$15,500

​

​​​​​​​​​​​​​
​Total​​​​​​​​
​​carrying​​​​​​​​​
​​value as of​Fair Value Measurements Using
​​June 30,​Inputs Considered as
​2022Level 1Level 2Level 3
​​​​​​​​​​​​​
Assets​​​​
Exchange traded securities(1)​$59,962​$59,962​$—​$—
Certificates of deposit(2)​14,500​14,500​—​—
Derivative instruments - cash flow hedges​11,026​—​11,026​—
Total assets​$85,488​$74,462​$11,026​$—
​​​​​​​​​​​​​
Liabilities​​​​
Contingent consideration​$5,000​$—​$—​$5,000
Derivative instruments - cash flow hedges​476​—​476​—
Total liabilities​$5,476​$—​$476​$5,000

​

(1)Included in available-for-sale investments on the balance sheet. During the quarter ended September 30, 2022, the Company sold all of its outstanding shares of ChemoCentryx Inc (CCXI). The cost basis and fair value of the Company’s available-for-sale equity investment in CCXI was $6.6 million and $36.0 million at June 30, 2022, respectively. The cost basis and fair value of the exchange traded investment grade bond funds as of September 30, 2022 was $25.0 million and $23.3 million, respectively. The cost basis and fair value of the exchange traded investment grade bond funds as of June 30, 2022 was $25.0 million and $23.9 million, respectively.

​

(2)Included in available-for-sale investments on the balance sheet. The certificates of deposit have contractual maturity dates within one year.

​

Fair value measurements of available for sale securities

Our available for sale securities are measured at fair value using quoted market prices in active markets for identical assets and are therefore classified as Level 1 assets.

Fair value measurements of derivative instruments

In October 2018, the Company entered into forward starting swaps designated as cash flow hedges on outstanding debt. The forward starting swaps reduce the variability of cash flow payments for the Company by converting the variable interest rate on the Company’s long-term debt described in Note 6 to that of a fixed interest rate. Accordingly, as part of the forward starting swaps, the Company exchanges, at specified intervals, the difference between floating and fixed interest amounts based on $200 million of notional principal as of September 30, 2022, which expired in October 2022. During the first fiscal quarter of 2023, the Company entered into an amended and restated credit agreement. The terms of the amended and restated agreement did not impact the effectiveness of the forward starting swaps as the Company continues to carry variable rate debt with a principal greater than the notional amount of the swap. The fair value of the designated derivative instrument is immaterial and is recorded within other short-term assets on the Consolidated Balance Sheet as of September 30, 2022. The fair value of the designated derivative instrument was $0.5 million, and was recorded within short-term liabilities on the Consolidated Balance Sheet as of June 30, 2022.

In May 2021, the Company entered into a new forward starting swap designated as a cash flow hedge on forecasted debt. The forward starting swap reduces the variability of cash flow payments for the Company by converting the variable interest rate on the Company’s forecasted variable interest long-term debt to that of a fixed interest rate. Accordingly, as part of the forward starting swap, the Company exchanges, at specified intervals, the difference between floating and fixed interest amounts based on $200 million of notional principal amount. The effective date of the swap is November 2022 with the full swap maturing in November 2025. The fair value of the derivative instrument was $16.7 million and $11.0 million as of September 30, 2022 and June 30, 2022, respectively, which is recorded within other long-term assets on the Consolidated Balance Sheet.

Changes in the fair value of the designated hedged instruments are reported as a component of other comprehensive income and reclassified into interest expense over the corresponding term of the cash flow hedge. The Company reclassified $0.4 million to interest expense and related tax benefits of $0.1 million during the quarter ended September 30, 2022. The Company reclassified $2.1 million to interest expense and related tax benefits of $0.5 million during the three months ended September 30, 2021. The instruments were valued using observable market inputs in active markets and therefore are classified as Level 2 liabilities.

Fair value measurements of contingent consideration

The Company has $15.5 million in contingent consideration recorded as of September 30, 2022, which is the fair value of contingent consideration related to the Asuragen and Namocell acquisitions. The Company is required to make contingent consideration payments of up to $105.0 million as part of the Asuragen acquisition agreement and up to $25.0 million as part of the Namocell acquisition agreement.

​

The Asuragen contingent agreement is based on achieving certain revenue thresholds by December 31, 2022 and December 31, 2023. The opening balance sheet fair value of the liabilities was $18.3 million, which was determined using a Monte Carlo simulation-based model discounted to present value. Assumptions used in these calculations are units sold, expected revenue, expected expenses, discount rate, and various probability factors. The contingent consideration related to Asuragen was $4.5 million and $5.0 million as of September 30, 2022 and June 30, 2022, respectively.

​

The Namocell contingent agreement is based on achieving certain revenue thresholds by December 31, 2022 and December 31, 2023. The opening balance sheet fair value of the liabilities was $10.6 million, which was determined using a Monte Carlo simulation-based model discounted to present value. Assumptions used in these calculations are units sold, expected revenue, expected expenses, discount rate, and various probability factors. As of September 30, 2022, the contingent consideration related to Namocell was $11.0 million.

​

As of September 30, 2022_,_ the Company's obligation for potential contingent consideration payments related to the Quad acquisition was relieved as both parties in the purchase agreement agreed the threshold would not be met. The Company’s obligation for potential

contingent consideration payments related to the B-Mogen acquisition was relieved as there is a remote likelihood that the revenue thresholds and product milestones would be achieved in the timeframe established within the purchase agreement. The Company reversed an accrual for the fair value of the contingent liabilities at the date of settlement during fiscal 2022.

​

The ultimate settlement of contingent consideration liabilities could deviate from current estimates based on the actual results of the financial measures described above. This liability is considered to be a Level 3 financial liability that is re-measured each reporting period. The change in fair value of contingent consideration for these acquisitions is included in general and administrative expense.

The following table presents a reconciliation of the liability measured at fair value on a recurring basis using significant unobservable inputs (Level 3) (in thousands):

​

​​​​​
​Quarter Ended​
​​September 30,​
​​2022​
​​​​​
Fair value at the beginning of period​$5,000​
Change in fair value of contingent consideration​(100)​
Additions​10,600​
Payments​—​
Fair value at the end of period​$15,500​

​

The use of different assumptions, applying different judgment to matters that inherently are subjective and changes in future market conditions could result in different estimates of fair value of our securities or contingent consideration, currently and in the future. If market conditions deteriorate, we may incur impairment charges for securities in our investment portfolio.

Fair value measurements of other financial instruments – The following methods and assumptions were used to estimate the fair value of each class of financial instrument for which it is practicable to estimate fair value.

Cash and cash equivalents, certificates of deposit, accounts receivable, and accounts payable – The carrying amounts reported in the consolidated balance sheets approximate fair value because of the short-term nature of these items.

Long-term debt – The carrying amounts reported in the consolidated balance sheets for the amount drawn on our line-of-credit facility and long-term debt approximates fair value because our interest rate is variable and reflects current market rates.

​

Note 6. Debt and Other Financing Arrangements:

On August 31, 2022, the Company entered into an amended and restated Credit Agreement (the Amended Credit Agreement). This replaced the revolving line-of-credit and term loan (the prior Credit Agreement), which provided for a revolving credit facility of $600.0 million and could be increased by an additional $200.0 million subject to certain conditions, and a term loan of $250.0 million. The prior Credit Agreement was bearing interest at a variable rate and would have matured on August 1, 2023.

The Amended Credit Agreement provides for a revolving credit facility of $1 billion, which can be increased by an additional $400 million subject to certain conditions. Borrowings under the Amended Credit Agreement may be used for working capital and expenditures of the Company and its subsidiaries, including financing permitted acquisitions. At the closing on August 31, 2022, the Company borrowed approximately $350 million pursuant to the Amended Credit Agreement for working capital and for payment of outstanding debt under the Company’s prior credit agreement that was entered into on August 1, 2018. Borrowings under the Amended Credit Agreement bear interest at a variable rate.The current outstanding debt is based on the one-month Secured Overnight Financing rate (SOFR) plus an applicable margin. The applicable margin is determined from the total leverage ratio of the Company and updated on a quarterly basis. The annualized fee for any unused portion of the credit facility is currently 10 basis points.

The amended and restated Credit Agreement matures on August 1, 2027 and contains customary restrictive and financial covenants and customary events of default. As of September 30, 2022, the outstanding balance under the Credit Agreement was $264.7 million.

​

​

Note 7. Leases:

As a lessee, the company leases offices, labs, and manufacturing facilities, as well as vehicles, copiers, and other equipment. The Company recognizes operating lease expense on a straight-line basis over the lease term. Operating lease right-of-use assets and liabilities are recognized at commencement date based on the present value of lease payments over the lease term. The discount rate used to calculate present value is Bio-Techne’s incremental borrowing rate or, if available, the rate implicit in the lease. Bio-Techne determines the incremental borrowing rate for each lease based primarily on its lease term and the economic environment of the applicable country or region. During the three months ended September 30, 2022, the Company recognized $0.9 million in variable lease expense and $3.8 million relating to fixed lease expense in the Condensed Consolidated Statements of Earnings and Comprehensive Income.

The following table summarizes the balance sheet classification of the Company’s operating leases and amounts of right of use assets and lease liabilities and the weighted average remaining lease term and weighted average discount rate for the Company’s operating leases (asset and liability amounts are in thousands):

​

​​​​​​​​
​​​As of
​​​​​September 30,
​​Balance Sheet Classification​2022
Operating leases:​​​
Operating lease right of use assets​Right of Use Asset​$69,745​
​​​​​​​​
Current operating lease liabilities​Operating lease liabilities current​$12,115​
Noncurrent operating lease liabilities​Operating lease liabilities​64,756​
Total operating lease liabilities​​​​$76,871​
​​​​​​​​
Weighted average remaining lease term (in years):​​​8.47​
​​​​​​​​
Weighted average discount rate:​​​4.00%

​

The following table summarizes the cash paid for amounts included in the measurement of operating lease liabilities and right of use assets obtained in exchange for new operating lease liabilities for the three months ended (in thousands):

​

​​​​
​​Quarter ended
​​September 30,
​2022
Cash amounts paid on operating lease liabilities​$3,660
​​​​
Right of use assets obtained in exchange for lease liabilities​10,520

​

​

The following table summarizes the fair value of the lease liability by payment date for the Company’s operating leases by fiscal year (in thousands):

​

​​​​
​September 30, 2022
​​Operating
​​Leases
Remainder 2023​$14,201
2024​12,044
2025​10,907
2026​9,542
2027​7,724
Thereafter​24,900
Total​$79,318
Less: Amounts representing interest​2,447
Total Lease obligations​$76,871

​

Certain leases include one or more options to renew, with terms that extend the lease term up to five years. Bio-Techne includes the option to renew the lease as part of the right of use lease asset and liability when it is reasonably certain the Company will exercise the option. In addition, certain leases contain fair value purchase and termination options with an associated penalty. In general, Bio-Techne is not reasonably certain to exercise such options.

​

​

​

Note 8. Supplemental Equity and Accumulated Other Comprehensive Income (Loss):

Supplemental Equity

The Company has declared cash dividends per share of $0.32 in the three months ended September 30, 2022 and 2021.

Consolidated Changes in Equity (amounts in thousands)

​

​​​​​​​​​​​​​​​​​​​​​
​Bio-Techne Shareholders​​​
​​​​​​​​​​​​​Accumulated​​​​​​
​​​​​​​Additional​​​​Other​​​​​​
​​Common Stock​Paid-in​Retained​Comprehensive​Noncontrolling​​​
​​Shares​Amount​Capital​Earnings​Income(Loss)​Interest​Total
Balances at June 30, 202239,160​​392​​653,657​​1,122,921​​(75,200)​​(759)​​1,701,011
Net earnings-​​-​-​89,555​-​179​89,734
Other comprehensive loss-​​-​-​-​(16,762)​0​(16,762)
Reclassification of cumulative translation adjustment for Eminence to non-operating income​-​​-​​-​​-​​152​​(33)​​119
Elimination of noncontrolling equity interest from sale of Eminence-​-​-​-​-​613​613
Share repurchases(55)​(1)​-​(19,561)​-​-​(19,562)
Common stock issued for exercise of options107​1​9,422​(11,428)​-​-​(2,005)
Common stock issued for restricted stock awards11​​-​-​(6,427)​-​-​(6,427)
Cash dividends-​​-​-​(12,545)​-​-​(12,545)
Stock-based compensation expense-​-​14,364​-​-​-​14,364
Common stock issued to employee stock purchase plan9​​-​2,517​-​-​-​2,517
Employee stock purchase plan expense​-​​-​​97​​-​​-​​-​​97
Balances at September 30, 202239,232​$392​$680,057​$1,162,515​$(91,810)​$-​$1,751,154

​

​​​​​​​​​​​​​​​​​​​​​
​Bio-Techne Shareholders​​​
​​​​​​​​​​​​​Accumulated​​​​​​
​​​​​​​Additional​​​​Other​​​​​​
​​Common Stock​Paid-in​Retained​Comprehensive​Noncontrolling​​​
​​Shares​Amount​Capital​Earnings​Income(Loss)​Interest​Total
Balances at June 30, 202138,955​$390​$534,411​$1,085,461​$(57,291)​$8,263​$1,571,234
Net earnings​​​​​​​​​​69,615​​​​​(634)​​68,981
Other comprehensive income (loss)​​​​​​​(6,925)​(39)​(6,964)
Common stock issued for exercise of options295​3​36,345​(13,481)​​​22,867
Common stock issued for restricted stock awards20​0​0​(9,765)​​​(9,765)
Cash dividends​​​​​​(12,493)​​​​(12,493)
Stock-based compensation expense​​​​​11,396​​​​​11,396
Common stock issued to employee stock purchase plan3​0​1,358​​​​​1,358
Employee stock purchase plan expense​​​​​341​​​​​341
Balances at September 30, 202139,273​$393​$583,851​$1,119,337​$(64,216)​$7,590​$1,646,955

​

​

​

Accumulated Other Comprehensive Income

The components of other comprehensive income (loss) consist of changes in foreign currency translation adjustments and changes in net unrealized gains (losses) on derivative instruments designated as cash flow hedges. The Company reclassified $0.5 million, net of taxes, from accumulated other comprehensive income (loss) to earnings during the three months ended September 30, 2022.

The accumulated balances related to each component of other comprehensive income (loss) attributable to Bio-Techne, net of tax, are summarized as follows:

​

​​​​​​​​​​
​​Unrealized​​​​​​
​​Gains​Foreign​​​
​​(Losses) on​Currency​​​
​​Derivative​Translation​​​
​InstrumentsAdjustmentsTotal
Balance as of June 30, 2022​$8,069​$(83,269)​$(75,200)
Other comprehensive income (loss) before reclassifications, net of taxes, attributable to Bio-Techne​4,376​(21,457)​(17,081)
Reclassification from loss on derivatives to interest expense, net of taxes, attributable to Bio-Techne(1)​319​​​​​319
Reclassification of cumulative translation adjustment for Eminence to non-operating income, net of taxes, attributable to Bio-Techne​​—​​152​​152
Balance as of September 30, 2022(2)​$12,764​$(104,574)​$(91,810)

​

​​​​​​​​​​
​​Unrealized​​​​​​
​​Gains​Foreign​​​
​​(Losses) on​Currency​​​
​​Derivative​Translation​​​
​InstrumentsAdjustmentsTotal
Balance as of June 30, 2021 attributable to Bio-Techne​$(6,193)​$(51,098)​$(57,291)
Other comprehensive income (loss), net of tax before reclassifications, attributable to Bio-Techne​84​(8,607)​(8,523)
Reclassification from loss on derivatives to interest expense, net of taxes, attributable to Bio-Techne(1)​1,598​—​1,598
Balance as of September 30, 2021 (2)​$(4,511)​$(59,705)​$(64,216)

​

(1)Gains (losses) on the interest swap are reclassified into interest expense as payments on the derivative agreement are made. The Company reclassified ($417) to interest expense and recorded a related tax benefit of $98 during the quarter ended September 30, 2022. The Company reclassified ($2,091) to interest expense and a related tax benefit of $493 during the quarter ended September 30, 2021.

​

(2)The Company had a net deferred tax liability of $3,921 and a net deferred tax benefit of $1,391 included in the accumulated other comprehensive income loss as of September 30, 2022 and 2021, respectively.

​

Note 9. Earnings Per Share:

The following table reflects the calculation of basic and diluted earnings per share (in thousands, except per share amounts):

​​​​​​​​
​Quarter Ended​
​​September 30,​
​20222021​
Earnings per share – basic:​​​​​​​
Net earnings, including noncontrolling interest​$89,734$68,981​
Less net earnings (loss) attributable to noncontrolling interest​​179​(634)​
Net earnings attributable to Bio-Techne​$89,555​$69,615​
Income allocated to participating securities​(26)​(36)​
Income available to common shareholders​$89,529​$69,579​
Weighted-average shares outstanding – basic​39,232​39,094​
Earnings per share – basic​$2.28​$1.78​
​​​​​​​​
Earnings per share – diluted:​​​
Net earnings, including noncontrolling interest​$89,734​$68,981​
Less net earnings (loss) attributable to noncontrolling interest​​179​​(634)​
Net earnings attributable to Bio-Techne​$89,555​$69,615​
Income allocated to participating securities​(26)​(36)​
Income available to common shareholders​$89,529​$69,579​
Weighted-average shares outstanding – basic​39,232​39,094​
Dilutive effect of stock options and restricted stock units​1,311​2,064​
Weighted-average common shares outstanding – diluted​40,543​41,158​
Earnings per share – diluted​$2.21​$1.69​

​

The dilutive effect of stock options and restricted stock units in the above table excludes all options for which the aggregate exercise proceeds exceeded the average market price for the period. The number of potentially dilutive option shares excluded from the calculation was 1.1 million and 0.4 million for the quarter ended September 30, 2022 and 2021, respectively.

​

Note 10. Share-based Compensation:

During the quarter ended September 30, 2022 and 2021, the Company granted 0.6 million and 0.3 million stock options at weighted average grant prices of $377.72 and $481.84 and weighted average fair values of $118.60 and $118.47, respectively. During the quarter ended September 30, 2022 and 2021, the Company granted 21,963 and 13,929 restricted stock units at a weighted average fair value of $377.52 and $481.82, respectively. During the quarter ended September 30, 2022, the Company did not grant restricted common stock shares. During the quarter ended September 30, 2021, the Company granted 5,344 shares of restricted common stock shares at a weighted average fair value of $481.82.

Stock options for 165,030 and 336,565 shares of common stock with total intrinsic values of $41.1 million and $122.8 million were exercised during the quarter ended September 30, 2022 and 2021, respectively.

Stock-based compensation expense, inclusive of payroll taxes, of $15.1 million and $13.2 million was included in selling, general and administrative expenses for the quarter ended September 30, 2022 and 2021 respectively. Additionally, the company recognized $0.3 million of stock-based compensation costs in cost of goods sold during the quarter ended September 30, 2022 compared to $0.4 million in the comparative prior year period. As of September 30, 2022, there was $85.4 million of unrecognized compensation cost related to non-vested stock options, non-vested restricted stock units and non-vested restricted stock. The weighted average period over which the compensation cost is expected to be recognized is 1.8 years.

In fiscal 2015, the Company established the Bio-Techne Corporation 2014 Employee Stock Purchase Plan (ESPP), which was approved by the Company's shareholders on October 30, 2014, and which is designed to comply with IRS provisions governing employee stock purchase plans. 200,000 shares were allocated to the ESPP. For ESPP, the Company recorded stock-based compensation expense of $0.1 million for the quarter ended September 30, 2022 and $0.3 million for the quarter ended September 30, 2021.

​

​

Note 11. Other Income / (Expense):

​

The components of other income (expense) in the accompanying Statement of Earnings and Comprehensive Income are as follows:

​

​​​​​​​
​​Quarter Ended
​​September 30,
​20222021
Interest expense​$(3,790)​$(3,409)
Interest income​​433​​193
Other non-operating income (expense), net(1)​50,756​7,377
Total other income (expense)​$47,399​$4,161

​

(1)Primarily due to a $37.2 million gain on the sale of our ChemoCentryx investment and a $11.7 million gain on the sale of Eminence.

​

Note 12. Income Taxes:

The Company’s effective income tax rate for the first quarter of fiscal 2023 and 2022 was 13.5% and (2.4)%, respectively, of consolidated earnings before income taxes, inclusive of discrete items. The change in the Company’s tax rate for the quarter ended September 30, 2022 compared to September 30, 2021 was driven by a mix of increased net income and the dilutive effect the increased net income has on the favorable rate benefits, which are mainly related to share-based compensation.

The Company recognized total net benefits related to discrete tax items of $7.8 million during the quarter ended September 30, 2022, compared to $17.7 million during the quarter ended September 30, 2021. Share-based compensation excess tax benefit contributed $8.3 million in the quarter ended September 30, 2022, compared to $18.3 million in the quarter ended September 30, 2021.The Company recognized total other immaterial net discrete tax expense of $0.5 million in the quarter ended September 30, 2022, compared to $0.6 million of other immaterial net discrete tax expense in the quarter ended September 30, 2021.

​

​

Note 13. Segment Information:

The Company's management evaluates segment operating performance based on operating income before certain charges to cost of sales and selling, general and administrative expenses, principally associated with the impact of partially owned consolidated subsidiaries as well as acquisition accounting related to inventory, amortization of acquisition-related intangible assets and other acquisition-related expenses. The Protein Sciences and Diagnostics and Genomics segments both include consumables, instruments, services and royalty revenue.

The following is financial information relating to the Company's reportable segments (in thousands):

​

​​​​​​​
​​Quarter Ended
​​September 30,
​20222021
Net sales:​​​​
Protein Sciences​$199,949$197,186
Diagnostics and Genomics​69,904​60,985
Intersegment​(198)​(452)
Consolidated net sales​$269,655$257,719
​​​​​​​
Operating income:​​
Protein Sciences​$85,942$90,100
Diagnostics and Genomics​8,638​7,463
Segment operating income​$94,580​$97,563
Costs recognized on sale of acquired inventory​(300)​(1,512)
Amortization of acquisition related intangible assets​(19,283)​(18,389)
Impact of partially-owned consolidated subsidiaries(1)​647​(1,562)
Acquisition related expenses​(297)​2,377
Stock based compensation, inclusive of employer taxes​(15,458)​(13,860)
Restructuring costs​(2,170)​(1,185)
Corporate general, selling, and administrative expenses​(1,402)​(210)
Consolidated operating income​$56,317$63,222

​

(1) Includes the quarterly results of the partially-owned consolidated subsidiary prior to the sale of this partially-owned consolidated subsidiary to a third party

​

Note 14. Subsequent Events:

At the 2022 annual meeting of shareholders of the Company held on October 27, 2022, the shareholders approved an amendment and restatement of the Company’s articles of incorporation to increase the number of authorized shares of the Company’s common stock from 100,000,000 to 400,000,000 to allow the Company to issue a stock dividend as announced on November 1, 2022.

​

​

​

Previous: Cover and table of contents · Next: Item 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL